Clinical and experimental experience with factor Xa inhibitors

Area of Science:

• Cardiology
• Pharmacology
• Thrombosis Research

Background:

• Cardiovascular disease is a leading cause of mortality globally.
• Antithrombotic agents, particularly factor Xa inhibitors, are under intense investigation for improved cardiovascular treatments.
• Fondaparinux sodium is an approved factor Xa inhibitor with demonstrated efficacy.

Purpose of the Study:

• To evaluate the efficacy and tolerability of factor Xa inhibitors, specifically fondaparinux sodium, in managing cardiovascular conditions and thrombosis.
• To explore the role of fondaparinux sodium in preventing arterial and venous thrombotic events.

Main Methods:

• Review of clinical trial data for fondaparinux sodium, including PENTUA, PENTALYSE, PENTATHLON, PENTAMAKS, EPHESUS, PENTHIFRA, and PENTHIFRA-Plus.
• Analysis of fondaparinux sodium's effects on coagulation cascade and plaque remodeling.
• Assessment of bleeding complications and reversal strategies.

Main Results:

• Fondaparinux sodium demonstrated promising results in patients with acute coronary syndromes and coronary artery disease.
• Established efficacy and tolerability in preventing and treating deep vein thrombosis and pulmonary embolism.
• Fondaparinux sodium offers benefits over other anticoagulants but shows a higher incidence of bleeding complications compared to unfractionated heparin.

Conclusions:

• Factor Xa inhibitors, exemplified by fondaparinux sodium, hold significant clinical potential for preventing both arterial and venous thrombosis.
• While not a definitive cure for acute coronary syndromes, these agents offer hope for enhanced treatment strategies and reduced cardiovascular morbidity and mortality.
• The availability of reversal agents like factor VIIa is crucial for managing potential bleeding complications, especially in surgical patients.